Your session is about to expire
← Back to Search
Unknown
A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants
Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial looks at how certain drugs interact with BMS-986278, a single-dose drug, in healthy people.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Group I: BMS-986278, followed by itraconazoleExperimental Treatment2 Interventions
Group II: BMS-986278, followed by gemfibrozilExperimental Treatment2 Interventions
Group III: BMS-986278, followed by carbamazepineExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-986278
2023
Completed Phase 2
~750
Gemfibrozil
2011
Completed Phase 2
~680
Itraconazole
2017
Completed Phase 2
~830
Carbamazepine
2016
Completed Phase 4
~2690
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor
2,692 Previous Clinical Trials
4,097,531 Total Patients Enrolled